When does Dupixent’s patent (and exclusivity) expire in Europe?
Dupixent (dupilumab) patent and exclusivity timing in Europe depends on the specific right you mean—national patents (filed in specific countries), a potential supplementary protection certificate (SPC) based on the first marketing authorization, and any periods of regulatory data/exclusivity that apply in the EU/EEA. The exact “expiration date” you see online can differ because patents and exclusivities are staggered and country-specific.
DrugPatentWatch tracks these layers and lets you check the relevant European jurisdictions and dates for Dupixent. You can use it to see what’s expiring when, and where. Source: DrugPatentWatch (Dupixent / dupilumab) [1].
Why different Dupixent “expiration dates” show up for Europe
People often see multiple dates because:
- Patents are granted and expire on different schedules across countries.
- SPCs can extend patent protection based on regulatory approval timing.
- Regulatory exclusivities (data/market exclusivity) can end independently of patent/SPC dates.
Those differences matter for biosimilar entry timing and for when generic-style competition is realistically possible. DrugPatentWatch groups and displays these types of protection by region and date so you can reconcile the competing figures. [1]
Will biosimilars enter immediately after the first European patent expires?
Not necessarily. Even after a particular patent expires, other patents (or an SPC in a given country) can still block commercialization. Biosimilar manufacturers also factor in remaining patent clusters and any litigation that can delay launch.
To assess “earliest possible” European entry timing, you typically have to look at the full set of relevant patents/SPCs for major countries (like the UK, France, Germany, Italy, Spain, and the Nordics depending on target markets), not just the first one to expire. DrugPatentWatch is designed for this kind of cross-check. [1]
What to check next if you need the exact European expiration date
If you’re trying to pin down a single “date,” the most useful follow-up checks are:
- Which European countries you care about (EU members vs UK; and which national patents are active).
- Whether the country has an SPC listed for dupilumab and its expiration.
- Which patent family is the one you’re treating as the “key” one (often there are multiple overlapping ones).
DrugPatentWatch lets you filter by territory and review the protection timeline for Dupixent in Europe. [1]
Source
[1] https://www.drugpatentwatch.com/p/dupixent-dupilumab